DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

Information source: Roswell Park Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: Tamoxifen (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Roswell Park Cancer Institute

Official(s) and/or principal investigator(s):
Shicha Kumar, MD, Principal Investigator, Affiliation: Roswell Park Cancer Institute

Overall contact:
AskRPCI, Phone: 1-877-275-7724, Email: AskRPCI@roswellpark.org

Summary

This study will help to understand the interaction between the hormonal therapy Tamoxifen, estrogen receptors and certain genes in the cancer cell. This information may eventually help select the appropriate therapy for future patients with similar cancer.

Clinical Details

Official title: Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Investigate the status of ERά-p53 interaction in ERά-positive, p53-wild type breast tumors in untreated patients and examine how tamoxifen therapy modifies this reaction

Secondary outcome: Confirm the wild type status of p53 and analyze the functional status of p53 pathway by monitoring expression of selected p53-target genes in tumors in patients who have or have not been treated with tamoxifen

Detailed description: Women with abnormal mammogram or suspicious masses will undergo diagnostic core biopsies which will be analyzed for ER/PR and HER2Neu expression. For patients that are ER positive, P53 staining will be done. Women presenting tumors with an Allred score of 3 or greater status will be approached to participate. Women will be randomized to either standard of care surgical therapy or a 4 week intervention of Tamoxifen 20mg daily for 4 weeks prior to surgery. During the intervention, blood draws will be done to measure levels of tamoxifen metabolites in the blood and test for polymorphisms that may decrease levels of active metabolites. Women will undergo two blood draws for PK/PD and one for pharmacogenomics.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- The patient must consent to be in the study and must have signed an approved consent

form conforming to institutional guidelines

- The patient must be 18 years or older

- Core biopsy should definitively demonstrate invasive carcinoma

- Invasive carcinoma should be ERά receptor positive

- The tumor should be approximately 1 cm, but at least 5mm to account for variability

in imaging and imaging occult disease(physical exam, mammography, ultrasound).

- Patients in whom surgical excision of the tumor is part of standard of care

management

- ECOG of 0 or 1

- Negative serum or urine β-hCG pregnancy test at screening for patients of

child-bearing potential(this is routinely done if premenopausal and having surgery)

- Consent to participate in DBBR

Exclusion Criteria:

- Male patients are not eligible for this study

- Female patients with inoperable tumor and patients undergoing neo-adjuvant

chemotherapy

- Patients with diagnosis by FNA cytology

- Pregnant or lactating women

- Prior therapy for breast cancer, including irradiation, chemo-, immuno- and/or

hormonal therapy

- Patients receiving any hormonal therapy, e. g., birth-control pills, ovarian hormonal

replacement therapy, infertility medications, etc. are not eligible

- Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would

preclude the patients from being subjected to surgical excision

- Psychiatric or addictive disorders that would preclude obtaining informed consent

- Patients known or suspected to have hypercoagulable syndrome or history of venous or

arterial thrombosis, stroke, TIA, or pulmonary embolism

- Women who are post-menopausal defined as no menses for at least 12 months

- Women on selective serotonin reuptake inhibitors (SSRI) SSRI inhibits metabolism of

tamoxifen

- Women with non-invasive disease or microinvasion are not eligible

- Women undergoing neoadjuvant chemotherapy are not eligible

- Women currently on tamoxifen for prevention are not eligible

- Patients shall not receive any herbal/alternative therapies such as flaxseed or soy

products or black cohosh.

- Patients with a known mutation in p53 (Li Fraumeni Syndrome)

Locations and Contacts

AskRPCI, Phone: 1-877-275-7724, Email: AskRPCI@roswellpark.org

University of Chicago, Chicago, Illinois 60601, United States; Recruiting
Lucia Gutierrez, Phone: 773-834-7964, Email: lgutierrez2@surgery.bsd.uchicago.edu

Roswell Park Cancer Institute, Buffalo, New York 14263, United States; Recruiting

Additional Information

Starting date: December 2009
Last updated: May 18, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017